You are here

Our science / Clinical Trials / Find a Trial / NCT01710020

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

Back to Search Print Save as PDF Bookmark Trial

NCT01710020

Last updated on October 4, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Orlando, Florida, 32806 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
End-Stage Renal Disease, Hemodialysis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects with end-stage renal disease

- Subjects need hemodialysis 3 times weekly

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with evidence or history of clinically significant disease, excluding those
common for subjects with End-Stage Renal Disease (ESRD).

- Subjects with any condition possibly affecting drug absorption.

- Subjects with malignancies with the exception of adequately treated basal cell
carcinoma of the skin.

NCT01710020
Pfizer
Completed
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Non-Hodgkin Lymphoma, Follicular Lymphoma, Large B-Cell Lymphoma, Non-Small-Cell Lung Carcinoma, Renal Cell Carcinoma, Squamous Cell of Head and Neck Carcinoma, Malignant Melanoma
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
NCT01307267
All Genders
18+
Years
Multiple Sites
Renal Cell Carcinoma
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
NCT02315755
All Genders
18+
Years
Multiple Sites
Renal Cell Carcinoma
"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"
NCT03538717
All Genders
18+
Years
Multiple Sites
Renal Cell Cancer
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
NCT02493751
All Genders
18+
Years
Multiple Sites
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease
Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis
There were 2 study periods in this study. In the Period 1, CP-690,550 was to be administered approximately 1 to 2 hours following hemodialysis. If significant non-renal clearance of the drug occurred such that dialyzability of CP-690,550 could not be assessed in Period 1, a second period (Period 2) will be conducted. In Period 2, a single dose of drug will be administered approximately 4 hours prior to hemodialysis.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
  • End-Stage Renal Disease
  • Hemodialysis
Drug: CP-690,550
CP-690,550 10 mg oral powder for constitution
Experimental: CP-690,550
Intervention: Drug: CP-690,550
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
June 2003
June 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with end-stage renal disease
  • Subjects need hemodialysis 3 times weekly

Exclusion Criteria:

  • Subjects with evidence or history of clinically significant disease, excluding those common for subjects with End-Stage Renal Disease (ESRD).
  • Subjects with any condition possibly affecting drug absorption.
  • Subjects with malignancies with the exception of adequately treated basal cell carcinoma of the skin.
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01710020
A3921004
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now